BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor response in Kras-mutant non-small cell lung cancer

KRAS mutation is present in approximately 30% of human lung adenocarcinomas. Although recent advances in targeted therapy have shown great promise, effective targeting of KRAS remains elusive, and concurrent alterations in tumor suppressors render KRAS-mutant tumors even more resistant to existing t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Immunol Res
Autors principals: Adeegbe, Dennis O., Liu, Shengwu, Hattersley, Maureen M., Bowden, Michaela, Zhou, Chensheng W., Li, Shuai, Vlahos, Raven, Grondine, Michael, Dolgalev, Igor, Ivanova, Elena V., Quinn, Max M., Gao, Peng, Hammerman, Peter S., Bradner, James E., Diehl, J. Alan, Rustgi, Anil K., Bass, Adam J., Tsirigos, Aristotelis, Freeman, Gordon J., Chen, Huawei, Wong, Kwok-Kin
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6170698/
https://ncbi.nlm.nih.gov/pubmed/30087114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0077
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars